CUMBERLAND PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the quarter ended March 31, 2024, the following officers and directors of the Company adopted trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The material items of the trading plan are set forth in the table below:
| Name of the Director or Officer | Title of the Director or Officer | Date of Adoption | Duration of the Trading Plan | Maximum Dollar Amount to be Used in the Purchase of the Securities |
|---|---|---|---|---|
| A.J. Kazimi | Chief Executive Officer | March 13, 2024 | June 13, 2024 - December 20, 2024 | $10,000 |
| Kenneth J. Krogulski | Director | March 13, 2024 | June 13, 2024 - December 20, 2024 | $50,000 |
| Jamie R. Jones | Director | March 13, 2024 | June 13, 2024 - December 20, 2024 | $10,000 |
| Caroline R. Young | Director | March 13, 2024 | June 13, 2024 - December 20, 2024 | $5,000 |
First Amendment to Revolving Credit Loan Agreement
On May 6, 2024, the Company entered into a First Amendment to the Loan Agreement which provides an alternative to the financial covenant by delivering to the lender a borrowing base certificate and complying with certain borrowing base requirements which set forth a maximum revolver amount equal to (a) up to $20 million or (b) the sum of the Company's cash balances and eligible accounts receivable.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.